NYSE · Healthcare
Evolent Health, Inc. (EVH)
As-reported financials and recent SEC filings for Evolent Health, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.88B
Net income
$-534.5M
Net margin
-28.5%
Diluted EPS
$-5.07
ROE
-128.7%
P/E (TTM)
—
Market cap
$619.8M
Debt / equity
2.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $1.88B | $2.55B | $1.96B | $1.35B | $908.0M |
| Gross profit | $399.9M | $367.4M | $460.5M | $316.6M | $250.4M |
| Operating income | $-410.1M | $-40.5M | $-71.2M | $3.6M | $-42.4M |
| Net income | $-534.5M | $-61.6M | $-113.0M | $-19.2M | $-37.6M |
| Diluted EPS | $-5.07 | $-0.81 | $-1.28 | $-0.20 | $-0.44 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
S-82026-06-10
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →Go deeper on EVH
Search Evolent Health, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.